Wild Biotech

Company Overview

Snapshot

Founded in April 2019 by Neta Raab, Ido Bachelet, and Gal Zanir, Wild Biotech operates with 1–10 employees. The company has secured funding across one round from two investors, including Marius Nacht and Tech.bio. In June 2019, the company completed a Seed funding round.

Business overview

Wild Biotech is an Israeli startup developing an AI-powered drug discovery platform focused on creating new medicines. The company utilizes a proprietary annotated metagenomic database of wild animal microbiota, employing artificial intelligence to organize and analyze gut microbes based on associations with animal diets, activity, and lifespans. Wild Biotech's end-to-end process spans from field exploration to drug development and clinical trials, initially targeting inflammatory, immune, and gastrointestinal diseases with several lead compounds currently in the preclinical stage. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In March 2021, Wild Biotech garnered significant media attention from FierceBiotech and BioWorld for its innovative approach to drug discovery. The company's strategy involves searching gut microbes from wild animals to pursue new drugs for human diseases, highlighting a novel and potentially high-impact method within the pharmaceutical industry. This signals a strong validation of Wild Biotech's unique research methodology and its potential to disrupt traditional drug development pathways, attracting investor interest in its preclinical pipeline.

Company Intelligence Q&A

What is Wild Biotech's core technology?

Wild Biotech develops an AI-powered drug discovery platform that leverages an annotated metagenomic database of wild animal microbiota. This platform uses artificial intelligence to analyze gut microbes and identify potential new medicines.

When was Wild Biotech founded and by whom?

Wild Biotech was founded in April 2019 by Neta Raab, Ido Bachelet, and Gal Zanir.

Which therapeutic areas is Wild Biotech initially focusing on?

Wild Biotech is initially tackling inflammatory, immune, and gastrointestinal diseases, with several lead compounds currently in the preclinical stage.

What was a key development for Wild Biotech in March 2021?

In March 2021, Wild Biotech received media coverage from FierceBiotech and BioWorld for its innovative approach to drug discovery, focusing on gut microbes from wild animals to develop new human disease treatments.

Which investors participated in Wild Biotech's Seed funding round?

In June 2019, Wild Biotech completed a Seed funding round with participation from.